Sanofi-Aventis stands by safety of Ketek despite liver damage reports

Share this article:
Sanofi-Aventis said it is standing by the safety profile of its antibiotic Ketek (telithromycin) despite findings by doctors that three patients suffered severe liver damage after taking the drug. “With what we know now, we’ve concluded that these events do not alter the drug’s safety profile,” a Sanofi-Aventis spokesman told Reuters, adding that the side effects were infrequent and were mentioned in the prescribing information. US health officials urged doctors on Friday to watch patients taking Ketek for signs of liver problems and to stop treatment if symptoms developed. Physicians reported that three patients in North Carolina had developed severe liver damage and one of them died after being treated with Ketek. Ketek is sold in Europe, Japan and the US where the FDA approved it in 2004 to treat acute bacterial bronchitis and pneumonia. Sanofi-Aventis is in reportedly in discussions with all health authorities where Ketek is sold and said it would consider all safety measures and implement them if needed.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Sales

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.